You can view the full text of this article for free using the link below.

Title: Cytokine therapy: clinical and progressive status in cancer

Authors: Vemuri Praveen Kumar, Mamidi Sai Ratna Mounica, Tadikamalla N.L. Swetha, Gogineni V.S.N. Lakshmi, Tullimilli Anusri, Pemmaraju Lakshmi Amulya, Anne Sirisha

Addresses: Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India. ' Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India. ' Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India. ' Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India. ' Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India. ' Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India. ' Department of Biotechnology, KL University, Green Fields, Vaddeswaram, Guntur District, 522502, Andhra Pradesh, India

Abstract: Immunologic approaches to cancer therapy rely on two distinct capabilities of the immune system: targeting the tumour microenvironment by recognising molecules expressed to a greater extent on tumour cells than normal cells and generating immune responses that can kill tumour cells. Immunocytokines, which are fusion proteins composed of a recombinant monoclonal antibody and a cytokine, capitalise on both of these capabilities by combining the ability of tumour-specific antibodies selectively to target tumours with the broad-based immunomodulatory activities of cytokines. This review hypothesises the rationale for development of immunocytokines for cancer and discusses preclinical and clinical data on specific immunocytokines being investigated as potential cancer therapies.

Keywords: cytokine therapy; cancer therapy; cancer treatment; immunocytokines; monoclonal antibody; aldesleukin; tumour microenvironment; IL-2; hu14.18-IL-2; huKS-IL-2; immunology; tumour cells.

DOI: 10.1504/IJIS.2011.041724

International Journal of Immunological Studies, 2011 Vol.1 No.3, pp.264 - 271

Published online: 30 Dec 2014 *

Full-text access for editors Full-text access for subscribers Free access Comment on this article